Zhijin Chen, Presenter: Nothing to Disclose

Zhongmin Wang, Abstract Co-Author: Nothing to Disclose

Ju Gong, Abstract Co-Author: Nothing to Disclose

The purpose of this study was to examine the safety and clinical efficacy of CT-guided radioactive iodine-125 seeds implantation treatment in patients with vertebrae metastatic tumor.

We retrospectively analyzed 20 cases with vertebrae metastatic tumor, including 9 men and 11 women aged 50-79 years (mean age, 61.1years). We used TPS to reconstruct the 3D image of vertebrae metastatic tumor and work out the number and the dose rate distribution of 125I seeds. The MPD of 125I seed implantation was 90-130Gy. 24 Vertebrae metastatic tumor were treated by CT-guided radioactive iodine-125 seeds implanted. The median of 19 (range,4-43) 125I seeds were implanted. 

 20 cases were followed up for a median of 12 months (4-26 months). The rate of pain relief was 95%. The 6 months and 12 months local control rates were 80% and 30%, respectively. The median local control time was 9 months. Overall survival rates for 6 months and 12 months were 95% and 45%. The median survival time was 10 months.

CT-guided radioactive iodine-125 seeds implantation treatment in patients with vertebrae metastatic tumor is a safe, effective, and minimally invasive method.

CT-guided radioactive iodine-125 seeds implantation treatment in patients with vertebrae metastatic tumor is a safe, effective, and minimally invasive method.

Chen, Z, Wang, Z, Gong, J, Clinic Efficacy of CT-guided Iodine-125 Seed Implantation Therapy in Patients with Advanced Vertebrae Metastatic Tumor.  Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, December 1 - December 6, 2013 ,Chicago IL. http://archive.rsna.org/2013/13026078.html